A Reversal for Karyopharm Therapeutics Inc. (KPTI) Is Not Near. The Stock Rises Again

Investors sentiment decreased to 1.24 in 2019 Q2. Its down 0.36, from 1.6 in 2019Q1. It dropped, as 16 investors sold Karyopharm Therapeutics Inc. shares while 25 reduced holdings. 17 funds opened positions while 34 raised stakes. 51.03 million shares or 3.92% more from 49.11 million shares in 2019Q1 were reported.
Interest Incorporated owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 36,723 shares. D E Shaw And invested in 805,462 shares or 0.01% of the stock. The Ontario – Canada-based Royal Retail Bank Of Canada has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Us National Bank & Trust De has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Prelude Cap Mngmt Limited Liability Corp stated it has 1,524 shares or 0% of all its holdings. Fmr Ltd Liability holds 0% or 1.05M shares in its portfolio. Art Advsrs Limited Liability Company owns 0.03% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 102,937 shares. Cubist Systematic Strategies accumulated 84,504 shares or 0.01% of the stock. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Morgan Stanley owns 115,174 shares or 0% of their US portfolio. Dekabank Deutsche Girozentrale owns 32,800 shares. One Trading Lp reported 8,698 shares or 0% of all its holdings. Spark Investment Management owns 86,951 shares for 0.04% of their portfolio. The United Kingdom-based Legal & General Group Public Ltd Com has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Renaissance Ltd Company reported 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a huge mover today! The stock increased 4.00% or $0.42 during the last trading session, reaching $11. About 1.29 million shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has declined 48.81% since September 13, 2018 and is downtrending. It has underperformed by 48.81% the S&P500.
The move comes after 9 months positive chart setup for the $681.31M company. It was reported on Sep, 13 by Barchart.com. We have $11.77 PT which if reached, will make NASDAQ:KPTI worth $47.69 million more.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on November, 14. They expect $-0.89 EPS, down 12.66 % or $0.10 from last year’s $-0.79 per share. After $-0.71 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts 25.35 % negative EPS growth.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 5 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Karyopharm Therapeutics has $29 highest and $6 lowest target. $16.20’s average target is 47.27% above currents $11 stock price. Karyopharm Therapeutics had 7 analyst reports since March 15, 2019 according to SRatingsIntel. As per Friday, March 15, the company rating was maintained by Wedbush. The rating was maintained by RBC Capital Markets on Friday, March 15 with “Buy”. The rating was maintained by FBR Capital with “Buy” on Wednesday, March 20. H.C. Wainwright maintained it with “Buy” rating and $29 target in Friday, March 15 report. The company was maintained on Thursday, June 20 by H.C. Wainwright. JP Morgan upgraded it to “Overweight” rating and $1600 target in Tuesday, July 23 report.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Globenewswire.com which released: “Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019 – GlobeNewswire” on May 02, 2019, also Finance.Yahoo.com with their article: “Class Action Update – NFLX, KPTI & MNK – Bronstein, Gewirtz & Grossman, LLC – Yahoo Finance” published on September 13, 2019, Benzinga.com published: “86 Biggest Movers From Yesterday – Benzinga” on September 06, 2019. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Finance.Yahoo.com and their article: “Is Karyopharm Therapeutics Inc.’s (NASDAQ:KPTI) CEO Salary Justified? – Yahoo Finance” published on September 05, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: ViiV’s Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study – Benzinga” with publication date: August 22, 2019.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $681.31 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.